We are live on ! Find out more
TLOG

TetraLogic Pharmaceuticals Corporation
TLOG

Delisted

TLOG was delisted on the 3rd of November, 2016.

35 hedge funds and large institutions have $43.4M invested in TetraLogic Pharmaceuticals Corporation in 2014 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 3 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 6

52% more funds holding

Funds holding: 2335 (+12)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

47% less capital invested

Capital invested by funds: $81.2M → $43.4M (-$37.8M)

75% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 12

Holders
35
Holders Change
+12
Holders Change %
+52.17%
% of All Funds
1.01%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
18
Increased
3
Reduced
12
Closed
6
Calls
Puts
Net Calls
Net Calls Change

TLOG Hedge Fund Activity: Q1 2014 in Review

35 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in TetraLogic Pharmaceuticals Corporation (TLOG) for Q1 2014, worth a combined $43.4M — down 47% from $81.2M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new TLOG positions and 6 closed out — a net gain of 12 holders — while 3 added to existing stakes and 12 trimmed.

The largest buyer was First Eagle Investment Management, opening a new position worth an estimated $1.38M. The largest seller was Oppenheimer & Co, exiting entirely with an estimated $10.2M sold.

  • 35 institutional investors held TetraLogic Pharmaceuticals Corporation (TLOG) as of Q1 2014, up from 23 in Q4 2013.
  • Funds reported $43.4M of TetraLogic Pharmaceuticals Corporation stock for Q1 2014, down 47% quarter-over-quarter.
  • 18 funds opened new TetraLogic Pharmaceuticals Corporation positions in Q1 2014 and 6 closed out, a net change of +12 holders.
  • The largest TetraLogic Pharmaceuticals Corporation buyer in Q1 2014 was First Eagle Investment Management, an estimated $1.38M added.
  • The largest TetraLogic Pharmaceuticals Corporation seller in Q1 2014 was Oppenheimer & Co, an estimated $10.2M sold.

Based on aggregated 13F filings for Q1 2014.